Home » Stocks » DexCom

DexCom, Inc. (DXCM)

Stock Price: $380.63 USD -37.37 (-8.94%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 36.44B
Revenue (ttm) 1.82B
Net Income (ttm) 231.10M
Shares Out 95.74M
EPS (ttm) 2.16
PE Ratio 176.22
Forward PE 125.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $380.63
Previous Close $418.00
Change ($) -37.37
Change (%) -8.94%
Day's Open 395.23
Day's Range 380.11 - 398.00
Day's Volume 2,873,864
52-Week Range 145.23 - 456.23

More Stats

Market Cap 36.44B
Enterprise Value 35.60B
Earnings Date (est) Mar 2, 2021
Ex-Dividend Date n/a
Shares Outstanding 95.74M
Float 94.38M
EPS (basic) 2.48
EPS (diluted) 2.16
FCF / Share 2.76
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.57%
FCF Yield 0.73%
Payout Ratio n/a
Shares Short 4.14M
Short Ratio 5.06
Short % of Float 4.39%
Beta 0.79
PE Ratio 176.22
Forward PE 125.00
P/FCF Ratio 137.83
PS Ratio 20.02
PB Ratio 29.56
Revenue 1.82B
Operating Income 297.00M
Net Income 231.10M
Free Cash Flow 264.40M
Net Cash 839.00M
Net Cash / Share 8.76
Gross Margin 54.28%
Operating Margin 16.31%
Profit Margin 12.70%
FCF Margin 14.52%
ROA 6.15%
ROE 20.05%
ROIC 8.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (21)

Buy 14
Overweight 2
Hold 3
Underweight 0
Sell 2

Analyst Consensus: Buy

Price Target

$472.28*
(24.08% upside)
Low
350
Current: $380.63
High
540
Target: 472.28
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,4761,03271957340225916099.9076.3048.60
Revenue Growth43.08%43.58%25.33%42.61%55.09%62%60.16%30.93%57%-
Gross Profit93266449237827817610046.6035.9018.40
Operating Income142-186-42.50-63.90-57.10-21.50-28.90-55.70-44.80-45.30
Net Income101-127-50.20-65.60-57.60-22.40-29.80-54.50-44.70-55.20
Shares Outstanding91.1088.2086.3083.6079.8075.2071.1068.7065.6056.90
Earnings Per Share1.10-1.44-0.58-0.78-0.72-0.30-0.42-0.79-0.68-0.97
Operating Cash Flow31512392.0056.2049.0023.602.40-33.10-30.10-42.70
Capital Expenditures-180-67.10-66.00-55.70-33.30-16.20-7.90-9.50-8.00-6.90
Free Cash Flow13556.1026.000.5015.707.40-5.50-42.60-38.10-49.60
Cash & Equivalents1,5331,38654912411584.6055.6049.7082.9048.83
Total Debt1,1461,010328-2.304.606.807.00-0.53
Net Cash / Debt38837522112411380.0048.8042.7082.9048.30
Assets2,3951,91690440329218512310612177.16
Liabilities1,5121,25348511970.8044.4038.4029.0016.0016.17
Book Value88366341928422114084.1077.0010560.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DexCom, Inc.
Country United States
Employees 3,900
CEO Kevin Ronald Sayer

Stock Information

Ticker Symbol DXCM
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: DXCM
IPO Date April 14, 2005

Description

DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.